Spots Global Cancer Trial Database for TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma
Official Title: A Phase II Study of Transcatheter Arterial Chemoembolization (TACE) Combined With Anti-PD-1 Antibody （IBI308） in Patients With Advanced Hepatocellular Carcinoma
Study ID: NCT04297280
Conditions
Study Description
Brief Summary: The objective of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma as first line therapy.
Detailed Description: The transarterial chemoembolization (TACE) is commonly used for the treatment of advanced hepatocellular carcinoma. Early randomized trials suggested that TACE can be accepted as the standard treatment for advanced stage disease. However, outcome of patients treated with TACE in real-life cohorts is still very poor. Recent studies have also supported a safe combination of immune checkpoint inhibition with TACE. Therefore, the objective of this study is to evaluate the efficacy and safety of TACE combined with anti-pd-1 antibody in patients in advanced hepatocellular carcinoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, , China
Contact Details
Name: Peng Wang, MD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: Zhiqiang Meng, MD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
